Atypical CD8+ cutaneous T-cell lymphoma after immunomodulatory therapy

被引：31

作者：

Berthelot, Cindy

Cather, Jennifer

Jones, Dan

Duvic, Madeleine

机构：

[1] Univ Texas, MD Anderson Canc Ctr, Dept Dermatol, Houston, TX 77030 USA

[2] Univ Texas, SW Med Sch, Dallas, TX USA

[3] Baylor Med Ctr, Dallas, TX USA

来源：

CLINICAL LYMPHOMA & MYELOMA | 2006年 / 6卷 / 04期

关键词：

efalizumab; infliximab; mycosis fungoides; Sezary syndrome;

D O I：

10.3816/CLM.2006.n.008

中图分类号：

R73 [肿瘤学];

学科分类号：

100214 ;

摘要：

Systemic immunomodulatory agents have recently been approved for the treatment of rheumatoid arthritis and psoriasis. Although lymphomas are known to emerge in the setting of immunosuppressive therapy, it has not been well described or established for the newer biologic immune response modifiers. Herein, we describe 2 patients who developed unusual CD8(+) cutaneous lymphoproliferative disorders after treatment with efalizumab and infliximab. The mechanisms and occurrence of lymphoma after immune response modifiers are discussed.

引用

收藏

页码：329 / 332

页数：4

相关论文

共 24 条

[1]

*ABB LAB, 2004, HUM PACK INS

[2] Aggressive cutaneous T-cell lymphomas after TNFα blockade [J].

Adams, AE ;

Zwicker, J ;

Curiel, C ;

Kadin, ME ;

Falchuk, KR ;

Drews, R ;

Kupper, TS .

JOURNAL OF THE AMERICAN ACADEMY OF DERMATOLOGY, 2004, 51 (04) :660-662

[3] Review article: the risk of lymphoma associated with inflammatory bowel disease and immunosuppressive treatment [J].

Aithal, GP ;

Mansfield, JC .

ALIMENTARY PHARMACOLOGY & THERAPEUTICS, 2001, 15 (08) :1101-1108

[4] Haematopoietic malignancies in rheumatoid arthritis:: lymphoma risk and characteristics after exposure to tumour necrosis factor antagonists [J].

Askling, J ;

Fored, CM ;

Baecklund, E ;

Brandt, L ;

Backlin, C ;

Ekbom, A ;

Sundström, C ;

Bertilsson, L ;

Cöster, L ;

Geborek, P ;

Jacobsson, LT ;

Lindblad, S ;

Lysholm, J ;

Rantapää-Dahlqvist, S ;

Saxne, T ;

Klareskog, L ;

Feltelius, N .

ANNALS OF THE RHEUMATIC DISEASES, 2005, 64 (10) :1414-1420

[5] Rheumatoid arthritis and malignant lymphomas [J].

Baecklund, E ;

Askling, J ;

Rosenquist, R ;

Ekbom, A ;

Klareskog, L .

CURRENT OPINION IN RHEUMATOLOGY, 2004, 16 (03) :254-261

[6]

*BIOG ID, 2003, AM PACK INS

[7] Tumor necrosis factor antagonist therapy and lymphoma development - Twenty-six cases reported to the Food and Drug Administration [J].

Brown, SL ;

Greene, MH ;

Gershon, SK ;

Edwards, ET ;

Braun, MM .

ARTHRITIS AND RHEUMATISM, 2002, 46 (12) :3151-3158

[8] Risk of malignant lymphomas in patients with rheumatoid arthritis and in their first-degree relatives [J].

Ekström, K ;

Hjalgrim, H ;

Brandt, L ;

Baecklund, E ;

Klareskog, L ;

Ekbom, A ;

Askling, J .

ARTHRITIS AND RHEUMATISM, 2003, 48 (04) :963-970

[9] Cutaneous EBV-related lymphoproliferative disorder in a 15-year-old boy with AIDS: An unusual clinical presentation [J].

Fardet, L ;

Blanche, S ;

Brousse, N ;

Bodemer, C ;

Fraitag, S .

JOURNAL OF PEDIATRIC HEMATOLOGY ONCOLOGY, 2002, 24 (08) :666-669

[10] Does safety make a difference in selecting the right TNF antagonist? [J].

Fleischmann, R ;

Yocum, D .

ARTHRITIS RESEARCH & THERAPY, 2004, 6 (Suppl 2) :S12-S18